Brenite OÜ (Bioresearch in Engineered Nanomaterials for Innovative Technological Excellence), headquartered in Tallinn, Estonia, is a leading innovator in nanotechnological biomaterials. Leveraging its proprietary Brenite Carbon Nanoclusters (BCN®) technology, the company develops cutting-edge biological solutions for applications in nanomedicine, antibacterial and antiviral medical devices, veterinary sciences, dietary supplements, and biodegradable biopolymers.
The BCN® platform represents a groundbreaking advancement in nano-engineering, derived from sustainable plant-based raw materials. Designed to function either as an independent agent or as a molecular cargo carrier, BCN® exhibits a unique surface chemistry that confers antimicrobial, anti-inflammatory, and antioxidant properties. These attributes unlock transformative applications across cellular engineering, advanced therapeutics, biomanufacturing, and agricultural technologies.
Beyond biomedical applications, BCN® nanomaterials significantly enhance the performance of biodegradable biopolymers. Their integration into polymer matrices improves mechanical resistance, thermal stability, barrier properties, and biodegradability, addressing key challenges in the development of sustainable materials. This makes BCN® a powerful tool for industries requiring durable yet eco-friendly solutions, including biomedical engineering, packaging, and industrial manufacturing.
In response to the growing demand for sustainable materials, Brenite OÜ has developed an innovative bionanotechnology solution designed to enhance the properties of biodegradable biopolymers. By integrating BCN® into polymer matrices, the company significantly improves mechanical strength, stability, and functionality, expanding potential applications in biomedical, packaging, and industrial sectors.
Recognizing the challenges associated with nanomedicine, Brenite OÜ has pioneered the development of the world’s first universal carbon nanocluster delivery vehicle, utilizing three distinct BCN® Nanocluster groups. This innovation establishes a versatile and scalable platform for drug delivery, regenerative medicine, and bioengineering, offering novel solutions with enhanced efficacy, biocompatibility, and sustainability.
With a steadfast commitment to scientific excellence and technological innovation, Brenite OÜ is redefining the future of bionanotechnology.
Brenite OÜ
Tartu mnt 67/1-13b • 10115
Tallinn – Estonia
VAT: EE102786808
